MX2016015350A - 1h-1,8-naftiridin-2-onas como compuestos anti-proliferativos. - Google Patents

1h-1,8-naftiridin-2-onas como compuestos anti-proliferativos.

Info

Publication number
MX2016015350A
MX2016015350A MX2016015350A MX2016015350A MX2016015350A MX 2016015350 A MX2016015350 A MX 2016015350A MX 2016015350 A MX2016015350 A MX 2016015350A MX 2016015350 A MX2016015350 A MX 2016015350A MX 2016015350 A MX2016015350 A MX 2016015350A
Authority
MX
Mexico
Prior art keywords
naphthyridin
2ones
anti proliferative
proliferative compounds
compounds
Prior art date
Application number
MX2016015350A
Other languages
English (en)
Inventor
Satya Bhujanga Rao Adibhatla Kali
Chowdary Nannapaneni Venkaiah
Kompella Amala
Krishna GAMPA Venugopala
Ganganamoni Srinivasulu
Reddy Sirigireddy Balakrishna
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52589723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016015350(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of MX2016015350A publication Critical patent/MX2016015350A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevas 1H-1,8-naftiridin-2-onas antiproliferativas de la fórmula general (I) o sales de las mismas farmacéuticamente aceptables: en la cual los grupos variables son como se definen en la presente, y su preparación y uso en el tratamiento terapéutico de trastornos relacionados a la inhibición de tirosinas cinasas en animales de sangre caliente. Los compuestos pueden superar la resistencia al fármaco inducida por imatinib.
MX2016015350A 2014-06-06 2014-12-15 1h-1,8-naftiridin-2-onas como compuestos anti-proliferativos. MX2016015350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2781CH2014 2014-06-06
PCT/IN2014/000777 WO2015186137A1 (en) 2014-06-06 2014-12-15 1h-1,8- naphthyridin-2ones as anti proliferative compounds

Publications (1)

Publication Number Publication Date
MX2016015350A true MX2016015350A (es) 2017-05-10

Family

ID=52589723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015350A MX2016015350A (es) 2014-06-06 2014-12-15 1h-1,8-naftiridin-2-onas como compuestos anti-proliferativos.

Country Status (18)

Country Link
US (2) US9765072B2 (es)
EP (1) EP3152205A1 (es)
JP (1) JP2017516867A (es)
KR (1) KR20170016921A (es)
CN (1) CN106573929A (es)
AP (1) AP2016009604A0 (es)
AU (1) AU2014396394A1 (es)
BR (1) BR112016028674A2 (es)
CA (1) CA2950250A1 (es)
CL (1) CL2016003102A1 (es)
EA (1) EA201692371A1 (es)
HK (1) HK1231469A1 (es)
IL (1) IL249118A0 (es)
MA (1) MA39524A1 (es)
MX (1) MX2016015350A (es)
PH (1) PH12016502432A1 (es)
SG (1) SG11201610149YA (es)
WO (1) WO2015186137A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014396394A1 (en) * 2014-06-06 2016-12-08 Natco Pharma Limited 1H-1,8- naphthyridin-2ones as anti proliferative compounds
CN107663151B (zh) * 2016-07-28 2021-11-26 江苏豪森药业集团有限公司 甲磺酸氟马替尼的中间体合成方法
CN108473476B (zh) * 2016-10-13 2021-02-19 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基杂环类化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1973545T3 (pl) 2005-12-23 2013-05-31 Ariad Pharma Inc Bicykliczne Związki Heteroarylowe
KR20090018104A (ko) * 2006-05-08 2009-02-19 어리어드 파마슈티칼스, 인코포레이티드 아세틸렌계 헤테로아릴 화합물
CN101490053B (zh) * 2006-05-08 2013-09-11 阿里亚德医药股份有限公司 单环杂芳基化合物
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US9180127B2 (en) * 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
ES2636262T3 (es) 2010-01-29 2017-10-05 Hanmi Science Co., Ltd. Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora en las proteínas cinasas
AU2014396394A1 (en) * 2014-06-06 2016-12-08 Natco Pharma Limited 1H-1,8- naphthyridin-2ones as anti proliferative compounds

Also Published As

Publication number Publication date
BR112016028674A2 (pt) 2017-08-22
US20170349588A1 (en) 2017-12-07
US10047088B2 (en) 2018-08-14
US9765072B2 (en) 2017-09-19
PH12016502432A1 (en) 2017-03-06
SG11201610149YA (en) 2017-01-27
CL2016003102A1 (es) 2017-06-23
AP2016009604A0 (en) 2016-12-31
EA201692371A1 (ru) 2017-04-28
KR20170016921A (ko) 2017-02-14
JP2017516867A (ja) 2017-06-22
AU2014396394A1 (en) 2016-12-08
WO2015186137A1 (en) 2015-12-10
MA39524A1 (fr) 2018-01-31
EP3152205A1 (en) 2017-04-12
US20170114057A1 (en) 2017-04-27
CN106573929A (zh) 2017-04-19
CA2950250A1 (en) 2015-12-10
HK1231469A1 (zh) 2017-12-22
IL249118A0 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
UA117830C2 (uk) Похідні біпіразолу як інгібітори jak
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
WO2016109217A3 (en) Btk inhibitors
PH12016502353A1 (en) Pharmaceutical composition
TN2017000158A1 (en) Carbazole derivatives
TW201613577A (en) Pharmaceutical combinations
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MY201535A (en) Therapeutic compounds
PH12016502432A1 (en) 1h-1,8-naphthyridin-2-ones as anti proliferative compounds
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof
PH12017501736A1 (en) Indole derivatives
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
PH12017501134A1 (en) Fumagillol derivatives
MX2017008497A (es) Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética.
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.